Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/454)
-
Publication number: 20080103103Abstract: The invention provides compositions and methods of treating an ocular condition by administering to an eye of a patient having an ocular condition an effective amount of a catechin or polyphenol. The compositions and methods can be used to treat ocular conditions such as ocular infection, ocular inflammation, ocular cancer or benign eye tumors.Type: ApplicationFiled: October 30, 2006Publication date: May 1, 2008Inventors: Bahram Memarzadeh, Lyle Bowman
-
Publication number: 20080103193Abstract: The present invention pertains to methods for making compositions and compositions for treating pain and cachexia or AIDS wasting. In particular, the instant invention employs methods for making ?9-tetrahydrocannabinol (?9-THC) and ?9-tetrahydrocannabinolic acid (?9-THCA) from Cannabis sativa, and compositions for the treatment of these diseases.Type: ApplicationFiled: October 26, 2006Publication date: May 1, 2008Inventors: Trevor Percival Castor, Lorraine C. Rosenberry, Theodore A. Tyler, Richard J. Student
-
Publication number: 20080103179Abstract: The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate compound (e.g., topiramate) or an anticonvulsive sulfonylurea compound (e.g. zonisamide).Type: ApplicationFiled: June 15, 2007Publication date: May 1, 2008Inventors: Peter Y. Tam, Leland F. Wilson
-
Patent number: 7354951Abstract: The present invention relates to novel benzopyran ER-? agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-? mediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis. Formula (I), wherein G is —O—, —S(O)n, —CF2—, —C(O)—, —CR1H— or —CR2(OH)—; R is halo, (C1-C4)alkyl or R3—(CH2)m—; R1 is F, hydroxyl, cyano, trifluoromethyl, (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (C1-C4)alkoxy, (C1-C4)alkylcarbonyloxy or benzyl; R2 is trifluoromethyl or (C1-C4)alkyl; R3 is cyano, hydroxyl, (C2-C4)alkenyl, (C1-C4)alkoxy or (C1-C4)alkoxycarbonyl; n is 0, 1 or 2; and m is 0, 1 or 2; and pharmaceutically acceptable salts thereof.Type: GrantFiled: October 5, 2005Date of Patent: April 8, 2008Assignee: Eli Lilly and CompanyInventors: Bryan Hurst Norman, Timothy Ivo Richardson
-
Patent number: 7351695Abstract: The invention encompasses novel salts of topiramate, and pharmaceutically acceptable polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, or amorphous forms thereof, as well as pharmaceutical compositions and pharmaceutical unit dosage forms containing the same. In particular, the invention encompasses pharmaceutically acceptable salts of topiramate, including without limitation topiramate sodium, topiramate lithium, topiramate potassium, or polymorphs, solvates, hydrates, dehydrates, co-crystals, anhydrous, and amorphous forms thereof. The invention further encompasses novel co-crystals or complexes of topiramate, as well as pharmaceutical compositions comprising them. The invention also encompasses methods of treating or preventing a variety of diseases and conditions including, but not limited to, seizures, epileptic conditions, tremors, cerebral function disorders, obesity, neuropathic pain, affective disorders, tobacco cessation, migraines, and cluster headache.Type: GrantFiled: November 19, 2003Date of Patent: April 1, 2008Assignee: Ortho-McNeil Pharmaceuticals, Inc.Inventors: Öm Almarssoo, Jules Remenar, Matthew L. Peterson
-
Publication number: 20080064679Abstract: Water-soluble cannabinoid compounds that are agonists of CB1 and CB2 cannabinoid receptors are provided. The compounds are made water-soluble by derivatization of the alkyl side chain and/or the phenolic hydroxyl group of tetrahydrocannabinol. The water-soluble cannabinoids are useful for the treatment of appetite loss, pain, multiple sclerosis, nausea and vomiting, and epilepsy.Type: ApplicationFiled: June 23, 2005Publication date: March 13, 2008Inventors: Billy R. Martin, Raj K. Razdan, Anu Mahadevan
-
Patent number: 7338970Abstract: Pharmaceutical composition comprising 5 to 20% of an idazoxan salt or of idazoxan hydrate, 10 to 40% of microcrystalline cellulose, 1 to 5% of lubricant, 0.1 to 0.5% of colloidal silica and from 29.5% to 84.8% of lactose, with respect to the total mass.Type: GrantFiled: November 28, 2003Date of Patent: March 4, 2008Assignee: Pierre Fabre MedicamentInventors: Joël Bougaret, Jean-Louis Avan, Roland Segonds
-
Patent number: 7335666Abstract: Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.Type: GrantFiled: August 31, 2006Date of Patent: February 26, 2008Assignee: WyethInventors: Dahui Zhou, Gary Paul Stack
-
Patent number: 7332519Abstract: Spirocyclic cyclohexane compounds, methods for their production, pharmaceutical compositions containing these compounds, and the use of these spirocyclic cyclohexane compounds for treating conditions associated with the nociceptin/ORL1 receptor system, e.g. pain, drug withdrawal, anxiety, etc.Type: GrantFiled: December 23, 2004Date of Patent: February 19, 2008Assignee: Gruenenthal GmbHInventors: Claudia Hinze, Bernd Sundermann, Stefan Oberboersch, Werner Englberger, Elmark Friderichs, Sven Frormann, Babette-Yvonne Koegel, Klaus Linz, Beatrix Merla, Derek Saunders, Wolfgang Schroeder, Hans Schick, Birgitta Henkel, Helmut Sonnenschein
-
Publication number: 20080015232Abstract: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.Type: ApplicationFiled: March 29, 2005Publication date: January 17, 2008Inventors: David F. Wiemer, Jeffrey D. Neighbors, John A. Beutler
-
Patent number: 7311923Abstract: Disclosed is a harmful-insect-eliminating formed resin article, wherein the article contains a 1,2-polybutadiene resin and a volatile harmful-insect-eliminating component, e.g. eucalyptol and pulegone, in an amount effective for eliminating a harmful insect. A typical use of the formed article is an animal collar.Type: GrantFiled: March 6, 2003Date of Patent: December 25, 2007Assignee: Sumitomo Chemical Company, LimitedInventors: Kaori Tsubouchi, Kenzo Hayama
-
Publication number: 20070293428Abstract: A method for treating a joint pain in a subject comprising providing an effective amount of an anti-angiogenic agent to a synovial capsule adjacent to the joint.Type: ApplicationFiled: June 19, 2006Publication date: December 20, 2007Inventors: John M. Zanella, Sean M. Haddock
-
Patent number: 7304090Abstract: Fluorescein and derivatives have use in the treatment of a disease of a living animal body, including human, which disease is responsive to the inhibition of the cystic fibrosis transmembrane conductance regulator chloride channels, for instance polycystic kidney disease and secretory diarrhoea.Type: GrantFiled: July 12, 2001Date of Patent: December 4, 2007Assignee: The University of BristolInventors: David Noel Sheppard, Zhiwei Cai
-
Patent number: 7288543Abstract: A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3?, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosedType: GrantFiled: March 8, 2005Date of Patent: October 30, 2007Assignee: Eli Lilly and CompanyInventors: Howard Barff Broughton, Nuria Diaz Buezo, Charles Howard Mitch, Concepcion Pedregal-Tercero
-
Patent number: 7288560Abstract: The present invention relates to spirocyclic cyclohexane compounds, to methods for their production, to pharmaceutical compositions containing these compounds, to methods of treatment using such compounds and to the use of such spirocyclic cyclohexarie compounds for producing pharmaceutical compositions.Type: GrantFiled: December 23, 2004Date of Patent: October 30, 2007Assignee: Gruenenthal GmbHInventors: Claudia Hinze, Bernd Sundermann, Hans Schick, Birgitta Henkel
-
Patent number: 7285580Abstract: The present invention concerns novel methods for enhancing the mechanical performance of tissue adhesives and sealants which comprises employing a primer molecule in association with a tissue adhesive or sealant, wherein the primer molecule serves to enhance the strength of the interface between the tissue and the adhesive matrix. The primer molecules described herein function to interact with a protein present in the tissue, thereby altering its characteristics to make it more amenable to bonding with the adhesive matrix. Primer molecules may be applied to the tissue independently from the tissue adhesive or sealant or may be mixed with the tissue adhesive or sealant prior to application to the tissue.Type: GrantFiled: January 25, 2005Date of Patent: October 23, 2007Assignee: Protein Polymer Technologies, Inc.Inventor: Erwin R. Stedronsky
-
Patent number: 7279500Abstract: Cannabinoid agonists and antagonists are provided for use in the treatment of disorders such as acute and chronic pain, inflammation, loss of appetite, convulsions, multiple sclerosis, nausea and vomiting. The cannabinoid agonists and antagonists contain a sulfonamide moiety incorporated into the cannabinoid side chain, and the side chain itself may be saturated or unsaturated.Type: GrantFiled: June 24, 2003Date of Patent: October 9, 2007Assignee: Virginia Commonwealth UniversityInventors: Billy R. Martin, Raj K. Razdan, Roger G. Pertwee
-
Patent number: 7279499Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.Type: GrantFiled: April 8, 2004Date of Patent: October 9, 2007Assignee: Eli Lilly and CompanyInventors: Gregory Lee Durst, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
-
Patent number: 7268148Abstract: Acne-affected skin has been found to be accompanied by the presence of matrix-degrading enzymes such as MMPs and neutrophil elastase, induction of neutrophils, and a reduction in procollagen biosynthesis. This invention treats scarring and inflammation accompanying acne by administering, topically or systemically, at least one of (i) an inhibitor of the matrix degrading enzymes and (ii) a cytokine inhibitor that alleviates inflammation and thus also alleviate neutrophil infiltration. Alleviating the matrix degradation and renormalizing procollagen biosynthesis allows for reduced inflammation and better natural repair of acne-affected skin. Inhibiting cytokines alleviates induction of MMPs in resident skin cells, and also alleviates inflammation with its concommitant induction of neutrophils from the blood stream bringing MMPs and elastase into the acne lesion.Type: GrantFiled: June 27, 2005Date of Patent: September 11, 2007Assignee: Regents of the University of MichiganInventors: John J. Voorhees, Gary J. Fisher, Sewon Kang
-
Patent number: 7268132Abstract: The present invention is directed to chemical compositions of substituted thioacetamides, processes for the preparation thereof and uses of the compositions in the treatment of diseases.Type: GrantFiled: April 28, 2005Date of Patent: September 11, 2007Assignee: Cephalon, Inc.Inventors: Edward R. Bacon, Sankar Chatterjee, Derek Dunn, John P. Mallamo
-
Patent number: 7253207Abstract: Novel quinones are provided, as well as compositions comprising these novel quinones. Methods of using the novel quinones in treatment of various indications including cancer are also provided.Type: GrantFiled: August 2, 2004Date of Patent: August 7, 2007Assignee: Cellgate, Inc.Inventors: Andrei V. Blokhin, Benjamin Frydman, Laurence J. Marton, Karen M. Neder, Jerry Shunneng Sun
-
Patent number: 7253206Abstract: The present invention provides novel phenalenone derivatives of formula (I) which are formed by the microorganism Penicillium herquei Bainer & Sartory, DSM 14142, during fermentation.Type: GrantFiled: February 14, 2003Date of Patent: August 7, 2007Assignee: Sanofi-Aventis Deutschland GmbHInventors: Laszlo Vertesy, Michael Kurz, Ziyu Li, Luigi Toti
-
Patent number: 7238374Abstract: Endothelial cells have the natural property of releasing soluble factors into the fluid surrounding them, said factors altering the behavior of immune cells. In cell systems containing at least endothelial cells, the release of this type of factor, which promotes the proliferation of resting and weakly activated lymphocytes and at the same time inhibits the proliferation of highly activated lymphocytes and transformed lymphoblasts without impairing their other vital functions, is induced by administration of pentacyclic oxindole alkaloids but inhibited by the concurrent administration of tetracyclic oxindole alkaloids.Type: GrantFiled: February 20, 2001Date of Patent: July 3, 2007Inventors: Klaus Keplinger, Martin Wurm, Gerhard Laus
-
Patent number: 7235584Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of ?6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.Type: GrantFiled: June 25, 2003Date of Patent: June 26, 2007Assignee: Pharmos CorporationInventors: Aaron Garzon, George Fink
-
Patent number: 7230027Abstract: Compositions, methods, etc. for addressing the first-pass effect.Type: GrantFiled: March 16, 2005Date of Patent: June 12, 2007Assignee: Bioavailability Systems, L.L.C.Inventor: James W. Harris
-
Patent number: 7217734Abstract: The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer.Type: GrantFiled: November 7, 2002Date of Patent: May 15, 2007Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Venkatesh Krishnan, Charles Willis Lugar, III, Blake Lee Neubauer, Bryan Hurst Norman, Lance Allen Pfeifer, Timothy Ivo Richardson
-
Patent number: 7208477Abstract: The subject invention provides methods and compositions for the treatment of benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases. In the practice of the subject invention, and anti-convulsant agent, such as topiramate, is administered to an individual.Type: GrantFiled: December 1, 2003Date of Patent: April 24, 2007Assignee: University of Florida Research Foundation, Inc.Inventors: Nathan Andrew Shapira, Mary Catherine Lessig, Bonnie I. McLaurin
-
Patent number: 7192982Abstract: Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH2— or —CH2CH2—; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length.Type: GrantFiled: May 30, 2002Date of Patent: March 20, 2007Assignees: Ligand Pharmaceuticals, Inc., Eli Lilly and CompanyInventors: Dawn Alisa Brooks, Alan M. Warshawsky, Chahrzad Montrose-Rafezadeh, Anne-Reifel Miller, Lourdes Prieto, Isabel Rojo, Jose Alfredo Martin, Maria Rosario Gonzales Garcia, Alicia Torrado, Rafael Ferritto Crespo, Carlos Lamas-Peteira, Robert J. Ardecky, Maria Martin-Ortega Finger
-
Patent number: 7189757Abstract: The invention is directed to compositions used for treating Central Nervous System (CNS) disorders. In addition, the invention provides convenient methods of treatment of a CNS disorder. Furthermore, the invention provides methods of treating sleep disorders using compositions that remain active for a discrete period of time to reduce side effects. More specifically, the invention is directed to the compositions and use of derivatized, e.g., ester or carboxylic acid derivatized, antihistamine antagonists for the treatment of sleep disorders.Type: GrantFiled: October 16, 2002Date of Patent: March 13, 2007Assignee: Hypnion, Inc.Inventors: Dale M. Edgar, David G. Hangauer, Harry Jefferson Leighton, Emmanuel J. M. Mignot
-
Patent number: 7153837Abstract: This invention relates to an agent for the protection of retinal neurons which comprises, as an effective ingredient, sulfamate derivative having the following formula: and to a method for the protection of retinal neurons by using said sulfamate derivative.Type: GrantFiled: June 14, 2002Date of Patent: December 26, 2006Assignee: Ortho-McNeil Pharmaceutical Inc.Inventors: Kaoru Ishigaki, Hiroshi Kojima, Shigehisa Okaguchi, Shinji Yoneda, Hideaki Hara, Nobuaki Miyawaki
-
Patent number: 7144885Abstract: This invention relates to a novel fused tricyclic heterocycle of the formula (Ia, Ib) and its use for the treatment of hyper-proliferative disordersType: GrantFiled: February 21, 2003Date of Patent: December 5, 2006Assignee: Bayer Pharmaceuticals CorporationInventors: Chengzhi Zhang, Michael Burke, Zhi Chen, Jacques Dumas, Dongping Fan, Benjamin D. Jones, Gaetan Ladouceur, Wendy Lee, Barton Phillips, Scott M. Wilhelm, Qian Zhao
-
Patent number: 7135479Abstract: Compounds of the Formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa and bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.Type: GrantFiled: September 10, 2003Date of Patent: November 14, 2006Assignee: WyethInventors: Dahui Zhou, Gary Paul Stack
-
Patent number: 7125542Abstract: Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.Type: GrantFiled: February 9, 2001Date of Patent: October 24, 2006Assignee: Massachusetts Eye and Ear InfirmaryInventors: Joan W. Miller, Evangelos S. Gragoudas, Reem Z. Renno
-
Patent number: 7098188Abstract: The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.Type: GrantFiled: July 3, 2002Date of Patent: August 29, 2006Assignee: Ortho-McNeil Pharmaceutical., Inc.Inventors: Ahmed Abdel-Magid, Cynthia Maryanoff
-
Patent number: 7074824Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-?-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.Type: GrantFiled: July 31, 2002Date of Patent: July 11, 2006Assignee: Arqule, Inc.Inventors: Zhiwei Jiang, Dasharatha G. Reddy
-
Patent number: 7060725Abstract: The present invention is directed to novel compounds of the formula (I) wherein X, R1, R2, R3, R4, R5 and R6 are as described in the specification, processes for the preparation of and pharmaceutical compositions comprising said derivatives. The compounds of the present invention are useful for the treatment of epilepsy. The invention is further directed to a process for the preparation of compounds of formula (XX), wherein X, R3, R4, R5 and R6 are as described in the specification.Type: GrantFiled: May 8, 2003Date of Patent: June 13, 2006Assignee: Janssen Pharmaceutica N.V.Inventors: Ahmed Abdel-Magid, Cynthia Maryanoff, Steven Mehrman, Kirk Sorgi, Frank Villani, Cheryl Kordik, Allen B. Reitz, Bruce Maryanoff
-
Patent number: 7045549Abstract: Methods are provided for use in treating humans suffering from irritable bowel syndrome. In the subject methods, an effective amount of a nerve-acting agent, e.g., lidocaine, topiramate, mexiletine and gabapentin, etc., is administered to a human suffering from irritable bowel syndrome. Also provided are pharmaceutical compositions and kits for use in practicing the subject methods.Type: GrantFiled: November 8, 2002Date of Patent: May 16, 2006Assignee: The Board of Trustees of the Leland Stanford Jr. UniversityInventors: Raymond R. Gaeta, Lynn Cintron
-
Patent number: 7041650Abstract: The invention relates to novel pharmaceutically acceptable salts of anticonvulsant derivatives, processes for preparation of and pharmaceutical compositions containing said salts, useful in the treatment of epilepsy.Type: GrantFiled: January 3, 2003Date of Patent: May 9, 2006Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Ahmed Abdel-Magid, Cynthia Maryanoff
-
Patent number: 7038021Abstract: The object of present invention is to provide an immunoassay for dioxins which can rapidly and simply afford measured values having a good correlation with analytical values of dioxins by the official method (GC/MS method). The above object is achieved by using the monoclonal antibody of the present invention having not only a reactivity with the indicator isomer among 17 kinds of PCDDs and PCDFs each having a predetermined WHO-TEF value, but also a high cross-reactivity with several kinds of dioxin isomers having five or six chlorine atoms which contribute largely to a TEQ value, and also having a stable reactivity with the antigens in a measuring solvent.Type: GrantFiled: July 7, 2004Date of Patent: May 2, 2006Assignee: Kyoto Electronics Manufacturing Co., Ltd.Inventors: Yoko Takagi, Kazuyuki Sawadaishi, Chiwa Kataoka
-
Patent number: 7030162Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.Type: GrantFiled: September 26, 2002Date of Patent: April 18, 2006Assignee: POZEN Inc.Inventors: John R. Plachetka, Zakauddin T. Chowhan
-
Patent number: 7019024Abstract: The invention provides a pharmaceutical for treatment of neurological and neuropsychiatric disorders comprising a compound of the formula: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 9, 2001Date of Patent: March 28, 2006Assignee: Allelix Neuroscience Inc.Inventors: Vassil Iliya Ognyanov, Laurence A. Borden, Stanley Charles Bell, Jing Zhang
-
Patent number: 7008961Abstract: Carcinoma is treated in a patient by administration of Rhodamine-123 (Rh-123) orally or by intravenous injection of a treatment solution of Rh-123, ethyl alcohol, dextrose, and water in an amount sufficient to effect in vivo destruction of cancer cells. The treatment solution is made by mixing a stock solution of Rh-123 in a solution of 95% ethyl alcohol and 5% water (by volume) with a solution of 5% (by weight) dextrose in water. For prostate cancer, treatment is controlled by measuring the level of prostate specific antigen (PSA), or prostate specific acid phosphatase in the blood of the patient.Type: GrantFiled: August 25, 1999Date of Patent: March 7, 2006Assignee: Huntington Medical Research InstitutesInventors: Doris M. Arcadi, legal representative, John A. Arcadi, deceased
-
Patent number: 6962944Abstract: Beta-lapachone, which is poorly soluble in most pharmaceutically acceptable solvents, has demonstrated significant antineoplastic activity against human cancer lines. The present invention overcomes this significant limitation by teaching novel pharmaceutical compositions comprising a therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, and a pharmaceutically acceptable solubilizing carrier molecule, which may be at water-solubilizing carrier molecule such as hydroxypropyl-?-cyclodextrin, or an oil-based solubilizing carrier molecule, for enhancing the solubility of Beta-lapachone in aqueous solution. The therapeutically effective amount of Beta-lapachone, or a derivative or analog thereof, may be complexed with the pharmaceutically acceptable solubilizing carrier molecule in aqueous solution. The novel pharmaceutical compositions may be administered with a second anticancer agent or in combination with radiation therapy.Type: GrantFiled: October 10, 2001Date of Patent: November 8, 2005Assignee: Arqule, Inc.Inventors: Zhiwei Jiang, Dasharatha G. Reddy
-
Patent number: 6951880Abstract: This invention provides novel compounds possessing antibacterial and/or antifungal and/or antitumor activity. Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.Type: GrantFiled: May 15, 2003Date of Patent: October 4, 2005Assignee: Genelabs Technologies, Inc.Inventors: Christoher Don Roberts, Jesse Daniel Keicher, Mikail Hakan Gezginci, Mark Douglas Velligan
-
Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
Patent number: 6949582Abstract: A method of relieving analgesia and reducing inflammation using a cannabinoid delivery topical liniment composition containing from about 97.5% to about 99.5% by weight a 70% monohydric alcohol solution, and from about 0.5% to about 2.5% by weight of a synergistic cannabinoid mixture extracted from the female plant Cannabis sativa L, including in combination: 9-Tetrahydrocannabinol (delta-9-THC), 9-THC Propyl Analogue (THC-V), Cannabidiol (CBD), Cannabidiol Propyl Analogue (CBD-V), Cannabinol (CBN), Cannabichromene (CBC), Cannabichromene Propyl Analogue (CBC-V), Cannabigerol (CBG), terpenoids, and flavonoids. The liniment is applied topically, preferably by spraying, and the constituents of the mixture are absorbed through the skin and interact with cannabinoid receptors in the body and tissues of a human patient to produce therapeutic analgesic and anti-inflammatory effects without undesirable psychotropic side effects.Type: GrantFiled: September 13, 2002Date of Patent: September 27, 2005Inventor: Walter H. Wallace -
Patent number: 6943266Abstract: Novel polycyclic cannabinoid analogs are presented which have preferentially high affinities for the cannabinoid CB2 receptor sites. The improved receptor affinity makes these analogs therapeutically useful as medications in individuals and animals for treatment of pain, glaucoma, epilepsy, nausea associated with chemotherapy.Type: GrantFiled: October 18, 2000Date of Patent: September 13, 2005Assignee: University of ConnecticutInventors: Alexandros Makriyannis, Atmaram Khanolkar
-
Patent number: 6939986Abstract: The invention provides a multistep process for preparing 1,2-diamino compounds and pharmaceutically acceptable addition salts thereof from 1,2-epoxides.Type: GrantFiled: February 22, 2002Date of Patent: September 6, 2005Assignee: Hoffmann-La Roche Inc.Inventors: Martin Karpf, René Trussardi
-
Patent number: 6914072Abstract: The invention relates to the use of cannabinoid compounds (derivatives of tetrahydrocannabinol) for decreasing cell proliferation in a mammal.Type: GrantFiled: May 17, 2001Date of Patent: July 5, 2005Assignee: Indevus Pharmaceuticals, Inc.Inventors: Sumner Burstein, Lawrence Recht, Robert B. Zurier
-
Patent number: 6908902Abstract: Co-therapy for the treatment of neurological dysfunctions comprising administration of one or more fructopyranose sulfamates and erythropoietin.Type: GrantFiled: January 24, 2002Date of Patent: June 21, 2005Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Carlos Plata-Salaman, Virginia Smith-Swintosky
-
Patent number: 6906099Abstract: The present invention relates to the use of a composition that increases central nervous system GABA levels in a mammal, for the treatment of addiction to drugs of abuse and modification of behavior associated with addiction to drugs of abuse in said mammal.Type: GrantFiled: February 2, 2001Date of Patent: June 14, 2005Assignee: Brookhaven Science Associates, LLCInventors: Stephen L. Dewey, Jonathan D. Brodie, Charles R. Ashby, Jr.